Distant activity of comet C/2002 VQ94 (LINEAR): optical spectrophotometric monitoring between 8.4 and 16.8 au from the Sun

Spectrophotometric monitoring of distant comet C/2002 VQ94 (LINEAR) was performed with the 6-m telescope of SAO RAS and with the 2.5-m Nordic Optical Telescope between 2008 and 2013. During this period the comet was on the outbound segment of its orbit, between heliocentric distances of 8.36 au and 16.84 au. Analysis of the spectra revealed the presence of the CO$^+$ and N$_2^+$ emissions in the cometary coma at a distance of 8.36 au from the Sun. This distance is larger than ionic emissions have been detected in any previous objects. Only continuum, with no traces of emissions, was detected in the spectrum obtained in 2009 when the comet was at a distance of 9.86 au. From the spectra obtained in 2008, average column densities of 2.04$\times$10$^9$ mol cm$^{-2}$ for N$_2^+$ and 3.26$\times$10$^{10}$ mol cm$^{-2}$ for CO$^+$ were measured in the cometary coma. The derived values correspond to N$_2^+$/CO$^+$=0.06 within the projected slit. The parameter, which is used as an indicator of cometary activity, was measured as 2000 cm in 2008, and 800 cm in 2009 and 2011. The values correspond to dust production rates between 10-20 kg s$^{-1}$, 4-6 kg s$^{-1}$ and 3-5 kg s$^{-1}$ at 8.36, 9.86, and 13.40 au respectively. There is an obvious correlation between the decrease of the dust production rate of the nucleus and the disappearance of the emissions in the spectrum of C/2002 VQ94 (LINEAR) at heliocentric distances greater than 9 au. The colors and size of the nucleus of C/2002 VQ94 (LINEAR) were estimated from the images obtained during the late stage at a heliocentric distance of 16.84 au, when the activity had probable ceased. The B-V and V-R colors were estimated to be 1.07$\pm$0.05 and 0.54$\pm$0.03 respectively. The effective nucleus radius of 48$\pm$2 km is in agreement with the previously published results, obtained from the observations of the comet during its early inactive stage.Comment: Accepted for publication in Icarus; 19 pages, 4 tables, 9 figure

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk